Background-Sucralfate does not have potent anti-ulcerogenic actions in users of non-steroidal anti-inflammatory drugs (NSAIDs). However, sucralfate may influence intragastric haemostasis favourably. Aim-To investigate separately the effects of sucralfate on acute gastric and duodenal injury and on changes in intragastric bleeding induced by aspirin. Method-On three occasions, 24 healthy volunteers received three days' treatment with aspirin 900 mg twice daily together with placebo, sucralfate 2 g twice daily or sucralfate 1 g four times daily. Injury was assessed endoscopically and bleeding by spontaneous and biopsy induced bleeding intragastric washings. Ex vivo prostaglandin E2 (PGE2) synthesis and serum thromboxane were measured by using radioinmmunoassay. Results-Aspirin significantly inhibited ex vivo gastric mucosal PGE2 synthesis, reduced serum thromboxane, caused gastric erosions, and increased spontaneous and biopsy induced bleeding. Sucralfate had no significant effects on endoscopic injury but sucralfate 1 g four times daily significantly reduced spontaneous and biopsy induced bleeding. Similar trends were seen with sucralfate 2 g twice daily but the results were less consistent. Conclusion-Sucralfate does not affect aspirin induced acute gastric mucosal injury but reduces aspirin associated intragastric bleeding.
activity. '1-13 This action may contribute to sucralfate's established well known ability to prevent stress induced gastric bleeding."" As, in these circumstances, sucralfate's predominant intragastric action may be on haemostasis' 1-13 rather than ulceration, we investigated its effects on acute aspirin induced intragastric mucosal erosions, mucosal damage and bleeding to see whether these effects could be differentiated.
Methods
This was a double blind, placebo controlled, crossover comparison with randomisation according to Latin square design. Each treatment period was of three days duration with a washout period between treatments of 11 days. Our previous studies have shown that erosions heal within two to three days6 and an 11 day washout period is associated with no carry over effects attributable to the previous treatment. '8 Each subject received, under blinded, randomised conditions, each of the following dosage regimens: aspirin 900 mg twice daily with placebo; aspirin 900 mg twice daily with sucralfate 2 g twice daily; aspirin 900 mg twice daily with sucralfate 1 g four times daily.
SUBJECTS
Twenty four healthy volunteers were studied. The main exclusion criteria included hypersensitivity to aspirin, presence or history of peptic ulceration or significant dyspepsia, history of easy bruising or bleeding, bleeding abnormality detected during initial screening, anaemia, history of asthma, lactation, pregnancy, or unacceptable contraception.
Optimal prophylaxis of non-steroidal antiinflammatory drug (NSAID) induced ulcers and their complications remains elusive. 1 At the end of the endoscopy, four mucosal biopsy specimens were taken from the greater curve at approximately 50 cm from the teeth using a standard 2 mm cup biopsy forceps. The endoscope was withdrawn and subjects were immediately intubated with a prepared orogastric tube. The gastric mucosa was washed with 100 ml water five minutes after mucosal biopsy and again after a further five minutes. During this time subjects lay rocking on their left hand side only so that the bleeding biopsy site was selectively washed. The recovered blood was measured using the orthotolidine reaction, and corrected for spontaneous mucosal bleeding as described previously.6 18 19 
EICOSANOIDS
The four biopsy specimens were divided into pairs and washed in Tris buffered saline (TBS). Each pair of biopsy specimens was then vortexed in 500 RI TBS for one minute at room temperature. The biopsy specimens were then removed and weighed, and the supernatant stored at -70°C until assay. Prostaglandin E2 (PGE2) in the unextracted supernatant was measured using specific radioimmunoassays.6 21 PGE2 was expressed as pg/mg wet weight of gastric mucosa.
SERUM THROMBOXANE
This was assayed in 12 of the subjects. Immediately after endoscopy, 10 ml blood was taken and allowed to clot for 30 minutes at 37°C.5 Serum thromboxane was measured in separated serum from these samples using a radioimmunoassay.6 STATISTICS AND POWER Analysis of variance was used to identify statistically significant differences. Bleeding values -basal microbleeding, bleeding per erosion and biopsy induced bleeding -as well as the number of lesions detected endoscopically tend to have a skewed distribution which approximates to normal after logarithmic transformation. The data were analysed in their logarithmic form. For analyses involving numbers of lesions, subjects with no detectable lesions were regarded as having 0 5 lesions to allow an analysis in this way. Based upon previous data,6 the present study was designed to have the power to detect a reduction in microbleeding from 10 uV1/0 minutes to 5*6 ,u/10 minutes (1-P=0 8) or 5-1 p1l/10 minutes (1-I3=09), based upon two-tailed testing and Ox=0 05.
Results

SUBJECTS
Twenty four volunteers were enrolled into the study. Twenty three completed all study periods successfully and formed the basis of the analysis. One subject had food in the stomach preventing visualisation at the final assessment: all data from this subject were excluded from analysis.
GASTRIC MUCOSAL SYNTHESIS OF PROSTAGLANDIN E2
There was a significant inhibition of ex vivo gastric mucosal PGE2 synthesis (p<0-001) when aspirin was given over the three day period (table 1) . Sucralfate did not seem to attenuate this reduction in PGE2 synthesis association with aspirin. There was no significant difference in gastric mucosal PGE2 synthesis rates between the three treatment arms. Aspirin 22-9 (15*9-37*9) 3*2*** (1-6-6-2) Aspirin+sucralfate 17-8 (11-5-27-5) 3-7*** (2 0-7-0) (1 g qid) Aspirin+sucralfate 14-1 (9-0-19-8) 4-0*** (2-3-6-8) (2 g bid) ***p<0-001 compared with baseline. qid=for times a day; bid=twice a day. SERUM THROMBOXANE These changes in mucosal PGE2 synthesis were reflected by similar changes in the serum thromboxane concentrations (table 2) . Thus, at baseline before ingestion of aspirin serum thromboxane was 9 1 (6-8-12-2) ng/ml and fell to essentially unrecordable concentrations after treatment with aspirin or placebo (p<0001). Co-administration of sucralfate did not affect this reduction in serum thromboxane.
MUCOSAL EROSIONS
Gastric erosions None of the subjects had any erosions before any of the treatment periods. After three days of aspirin treatment this rose significantly to 5.3 (2 9-9A4) erosions throughout the stomach (p<0 001; table 3). Sucralfate did not significantly affect the number of erosions after aspirin treatment. Likewise, the distribution between antrum and body was not affected by sucralfate treatment.
Duodenal erosions
Duodenal damage with all three regimens was infrequent. There was no significant difference in the number of erosions in the duodenum when aspirin was co-administered with either sucralfate 1 g four times daily or 2 g twice daily compared with aspirin with placebo.
BLEEDING PARAMETERS
Validation
In initial experiments, addition of sucralfate suspension to gastric juice in concentrations from 0 to 5% (v/v) did not affect the quantitative assay of blood recovered ex vivo. Similarly, blood added to gastric aspirates was measured accurately and quantitatively whether sucralfate was added or not. qid=four times a day; bid=twice a day. 4-2*** (2-1-8-2) Aspirin+sucralfate (2 g bid) 0 6.9*** (3-5-13-6) ***p<0.001 compared with baseline.
qid=four times a day; bid=twice a day.
Microbleeding
After aspirin with placebo, the median rate of gastric microbleeding rose by a factor of 13-8 (95% confidence interval (CI) 7-8-24-5, p<0 001 compared with baseline) from 1 6 (1 1-2 3) ,ul per 10 minutes to 24-6 (15-9-37-9) ,ul per 10 minutes (table 4) . There were also significant increases, by factors respectively of 5-1 (2 9-9d1) and 5-8 (3-2-10.2) with the two sucralfate regimens.
However, analysis of variance showed that there were significant differences between the three treatments for absolute bleeding values on day 3 (p<0O05) and for the rise from baseline (p<0 05). Pairwise comparisons showed that the rise with aspirin plus sucralfate 1 g four times daily was significantly less than for aspirin with placebo (p=0037, paired t test). When the absolute final value of microbleeding for aspirin plus sucralfate 1 g four times daily (10-5 ,ul, 95% CI 5-9-18-7 [lI) was compared with the absolute final value for aspirin RIu, 95% CI 15-9-37-9 ,ul), this was significantly reduced (p=0*018). For aspirin with sucralfate 2 g twice daily, pairwise comparisons also showed reduced spontaneous bleeding compared with aspirin plus placebo. These differences were at borderline levels of statistical significance for the increase in microbleeding (p=0052) and the absolute final value of 12-9 (6.6-25.4) ,ul per 10 minutes (p=0 08).
Biopsy induced bleeding
There was a significant increase in the amount of biopsy induced bleeding over five and 10 minutes when aspirin was administered with placebo (p<0 01; table 5). There was no significant increase for any of these values when aspirin was administered with sucralfate 1 g four times daily. However, bleeding did seem to increase (p=001) when aspirin was administered with sucralfate 2 g twice daily.
Bleeding per erosion Twelve subjects had erosions at the final endoscopy for all treatment periods. For these subjects, it was possible to calculate a value for spontaneous microbleeding per erosion (table 6 ). This fell from 2-57 (1-03-6&40) [l per erosion with aspirin plus placebo to 102 (037-2-81) p.1 per erosion when aspirin was co-administered with sucralfate 1 g four times daily (p=0065), and 1P05 (046-2.36) ,ul per erosion when aspirin was co-administered with sucralfate 2 g twice daily (p=0072).
Discussion
In this study the effects of aspirin on PGE2, thromboxane, erosions, and bleeding are very similar to those observed in previous studies of similar design and duration conducted in this department.6 [18] [19] [20] These studies have established the validity of the method. They have shown that assessment of the number of erosions is reproducible between individual endoscopists. Moreover, each endoscopist studied a cohort of volunteers to improve the reproducibility of repeated measurements. Our previous studies have also shown that the washout period used in this study is sufficient for erosions to heal, for the serum thromboxane concentration to return to normal, and for intragastric bleeding to be uninfluenced by treatment order. In the present study we found that sucralfate had no significant protective effects against the development of gastric erosions, but that several of our measures of intragastric bleeding were favourably influenced. Thus, aspirin caused significant increases in microbleeding and in biopsy induced bleeding and these, along with the amount of bleeding per erosion, were significantly reduced when sucralfate 1 g four times daily was co-administered with aspirin. Sucralfate 2 g twice daily also showed a trend towards a reduction in spontaneous microbleeding and in bleeding per erosion, although these were both at borderline levels of significance. Sucralfate 2 g twice daily did not, however, abrogate the increase in biopsy induced bleeding seen term is reduced to a greater extent than uncomplicated relapse.4 5 It is possible that sucralfate could reduce the incidence of NSAID induced haematemesis and melaena without reducing the development of ulcers, although it would be a formidable proposition to demonstrate this directly.
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